In a real-world study of adults living with neuromyelitis optica spectrum disorder (NMOSD) in Japan, Uplizna (inebilizumab) was linked to fewer relapses, generally stable disability, and less use of corticosteroids. In addition, the approved therapy’s safety profile was consistent with what had been observed in earlier studies. “Our…
Discussion
When I was diagnosed with neuromyelitis optica spectrum disorder (NMOSD), my greatest frustration wasn’t my inability to walk, the numerous tests and MRI scans, or even the number of needles. It was trying to articulate the severity of this disorder to my parents. My parents were both Indonesian, raised…
Discussion
Treatment with Soliris (eculizumab) substantially reduces the risk and frequency of relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against the aquaporin-4 (AQP4) protein. That’s according to a systematic review of published studies reporting results from clinical trials testing Soliris in this…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
